15-lipoxygenase-1 exerts its tumor suppressive role by inhibiting nuclear factor-kappa B via activation of PPAR gamma

Journal of Cellular Biochemistry

Volumn 112, Issue 9, 2011, Pages 2490-2501

  Cimen, I ^a   Astarci, E ^a   Banerjee, S ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

15 LIPOXYGENASE 1; Colorectal cancer; NF B; PPAR

Indexed keywords

13 HODE; 15 LIPOXYGENASE 1; 2 CHLORO 5 NITROBENZANILIDE; ANTINEOPLASTIC AGENT; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN P60; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANILIDES; ARACHIDONATE 15-LIPOXYGENASE; CELL NUCLEUS; CELL PROLIFERATION; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HCT116 CELLS; HT29 CELLS; HUMANS; I-KAPPA B PROTEINS; LINOLEIC ACIDS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; PHOSPHORYLATION; PPAR GAMMA; PROTEIN BINDING; PROTEIN TRANSPORT; RECOMBINANT PROTEINS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 84860389878     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23174     Document Type: Article

References (45)

1. Bharti AC, Aggarwal BB,. 2002. Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem Pharmacol 64: 883-888. (Pubitemid 35238030)
2. Bhattacharya S, Mathew G, Jayne DG, Pelengaris S, Khan M,. 2009. 15-Lipoxygenase-1 in colorectal cancer: A review. Tumour Biol 30: 185-199.
3. Bonizzi G, Piette J, Schoonbroodt S, Greimers R, Havard L, Merville MP, Bours V,. 1999. Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol 19: 1950-1960. (Pubitemid 29098253)
4. Brockman JA, Gupta RA, Dubois RN,. 1998. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115: 1049-1055. (Pubitemid 28485592)
5. Bull AW, Steffensen KR, Leers J, Rafter JJ,. 2003. Activation of PPAR gamma in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands for PPAR gamma. Carcinogenesis 24: 1717-1722. (Pubitemid 37419906)
6. Buroker NE, Barboza J, Huang JY,. 2009. The IkappaBalpha gene is a peroxisome proliferator-activated receptor cardiac target gene. FEBS J 276: 3247-3255.
7. Chen F, Wang M, O'Connor JP, He M, Tripathi T, Harrison LE,. 2003. Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. J Cell Biochem 90: 732-744. (Pubitemid 37392464)
8. Cimen I, Tuncay S, Banerjee S,. 2009. 15-Lipoxygenase-1 expression suppresses the invasive properties of colorectal carcinoma cell lines HCT-116 and HT-29. Cancer Sci 100: 2283-2291.
9. Cuendet M, Pezzuto JM,. 2000. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 17: 109-157. (Pubitemid 32049022)
10. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM,. 1995. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803-812. (Pubitemid 3006324)
11. Garneau H, Alvarez L, Paquin MC, Lussier C, Rancourt C, Tremblay E, Beaulieu JF, Rivard N,. 2007. Nuclear expression of E2F4 induces cell death via multiple pathways in normal human intestinal epithelial crypt cells but not in colon cancer cells. Am J Physiol Gastrointest Liver Physiol 293: G758-G772. (Pubitemid 47605915)
12. Hayden MS, Ghosh S,. 2008. Shared principles in NF-kappaB signaling. Cell 132: 344-362.
13. Hsi LC, Wilson L, Nixon J, Eling TE,. 2001. 15-Lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. J Biol Chem 276: 34545-34552.
14. Hsi LC, Wilson LC, Eling TE,. 2002. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 277: 40549-40556. (Pubitemid 35215634)
15. Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, Schwabe JW,. 2008. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 15: 924-931.
16. Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S,. 2003. Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem 253: 141-149. (Pubitemid 37321720)
17. Kandouz M, Nie D, Pidgeon GP, Krishnamoorthy S, Maddipati KR, Honn KV,. 2003. Platelet-type 12-lipoxygenase activates NF-kappaB in prostate cancer cells. Prostaglandins Other Lipid Mediat 71: 189-204. (Pubitemid 36929790)
18. Karin M,. 2006a. NF-kappaB and cancer: Mechanisms and targets. Mol Carcinog 45: 355-361.
19. Karin M,. 2006b. Nuclear factor-kappa B in cancer development and progression. Nature 441: 431-436. (Pubitemid 44050137)
20. Kelavkar U, Wang S, Montero A, Murtagh J, Shah K, Badr K,. 1998. Human 15-lipoxygenase gene promoter: Analysis and identification of DNA binding sites for IL-13-induced regulatory factors in monocytes. Mol Biol Rep 25: 173-182. (Pubitemid 28324691)
21. Kim EK, Kwon KB, Koo BS, Han MJ, Song MY, Song EK, Han MK, Park JW, Ryu DG, Park BH,. 2007. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway. Int J Biochem Cell Biol 39: 1260-1275.
22. Krishnamoorthy S, Honn KV,. 2008. Eicosanoids in tumor progression and metastasis. Subcell Biochem 49: 145-168.
23. Mayo MW, Baldwin AS,. 2000. The transcription factor NF-kappaB: Control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470: M55-M62. (Pubitemid 30155606)
24. Michalik L, Desvergne B, Wahli W,. 2004. Peroxisome-proliferator- activated receptors and cancers: Complex stories. Nat Rev Cancer 4: 61-70. (Pubitemid 38082154)
25. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM,. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93: 229-240. (Pubitemid 28180856)
26. Nixon JB, Kamitani H, Baek SJ, Eling TE,. 2003. Evaluation of eicosanoids and NSAIDs as PPARgamma ligands in colorectal carcinoma cells. Prostaglandins Leukot Essent Fatty Acids 68: 323-330. (Pubitemid 36535257)
27. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK,. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437: 759-763. (Pubitemid 41486547)
28. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y,. 2004. Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 4: 465-477. (Pubitemid 39406260)
29. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM,. 1998. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052. (Pubitemid 28417337)
30. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C,. 1999. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3: 799-804. (Pubitemid 29323058)
31. Sendobry SM, Cornicelli JA, Welch K, Bocan T, Tait B, Trivedi BK, Colbry N, Dyer RD, Feinmark SJ, Daugherty A,. 1997. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br J Pharmacol 120: 1199-1206. (Pubitemid 27149668)
32. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DE,. 1999. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 20: 1985-1995. (Pubitemid 29476127)
33. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM,. 2005. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res 65: 11486-11492. (Pubitemid 41821706)
34. Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy O, Morris JS, Xiao L, Newman RA, Yang P, Lippman SM,. 2010. Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res (Phila Pa) 3: 829-838.
35. Straus DS, Glass CK,. 2007. Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends Immunol 28: 551-558. (Pubitemid 350101420)
36. Van Waes C,. 2007. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13: 1076-1082. (Pubitemid 46424045)
37. Wahli W,. 2008. A gut feeling of the PXR, PPAR and NF-kappaB connection. J Intern Med 263: 613-619. (Pubitemid 351678588)
38. Wan H, Yuan Y, Qian A, Sun Y, Qiao M,. 2008. Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells. Biomed Pharmacother 62: 466-472.
39. Wang S, Liu Z, Wang L, Zhang X,. 2009. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 6: 327-334.
40. Wen X, Li Y, Liu Y,. 2010. Opposite action of peroxisome proliferator-activated receptor-{gamma} in regulating renal inflammation: Functional switch by its ligand. J Biol Chem 285: 29981-29988.
41. Yang WL, Frucht H,. 2001. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22: 1379-1383. (Pubitemid 32898693)
42. Yang XY, Wang LH, Mihalic K, Xiao W, Chen T, Li P, Wahl LM, Farrar WL,. 2002. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. J Biol Chem 277: 3973-3978. (Pubitemid 34968651)
43. Yoshinaga M, Buchanan FG, DuBois RN,. 2004. 15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK 1/2 signaling in colon carcinoma cells. Prostaglandins Other Lipid Mediat 73: 111-122. (Pubitemid 38446475)
44. Zhu H, Glasgow W, George MD, Chrysovergis K, Olden K, Roberts JD, Eling T,. 2008. 15-Lipoxygenase-1 activates tumor suppressor p53 independent of enzymatic activity. Int J Cancer 123: 2741-2749.
45. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I,. 2006. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 25: 1225-1241.